BD-1008
 | |
| IUPAC ime | |
|---|---|
2-(3,4-dichlorophenyl)-N-methyl-N-(2-pyrrolidin-1-ylethyl)ethanamine | |
| Identifikatori | |
| CAS broj | 138356-08-8  |
| ATC kod | none |
| PubChem | CID 126388 |
| Hemijski podaci | |
| Formula | C15H22Cl2N2 |
| Molarna masa | 301.254 g/mol |
| |
BD-1008 je antagonist sigma receptora, koji blokira efekte kokaina u studijama na životinjama. On potencijalno može da bude koristan u razvoju antidota za lečenje kokainskog predoziranja.[1][2][3][4]
Vidi još
[уреди | уреди извор]Reference
[уреди | уреди извор]- ^ Monnet FP, de Costa BR, Bowen WD (1996). „Differentiation of sigma ligand-activated receptor subtypes that modulate NMDA-evoked [3H]-noradrenaline release in rat hippocampal slices”. British Journal of Pharmacology. 119 (1): 65—72. PMC 1915737
. PMID 8872358.
- ^ Matsumoto RR, McCracken KA, Pouw B, Miller J, Bowen WD, Williams W, De Costa BR (2001). „N-alkyl substituted analogs of the sigma receptor ligand BD1008 and traditional sigma receptor ligands affect cocaine-induced convulsions and lethality in mice”. European Journal of Pharmacology. 411 (3): 261—73. PMID 11164383.
- ^ Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, Bowen WD (2001). „Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice”. European Journal of Pharmacology. 419 (2-3): 163—74. PMID 11426838. doi:10.1016/S0014-2999(01)00968-2.
- ^ Matsumoto RR, Gilmore DL, Pouw B, Bowen WD, Williams W, Kausar A, Coop A (2004). „Novel analogs of the sigma receptor ligand BD1008 attenuate cocaine-induced toxicity in mice”. European Journal of Pharmacology. 492 (1): 21—6. PMID 15145701. doi:10.1016/j.ejphar.2004.03.037.
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
